IgA Nephropathy: when the gut causes inflamed kidneys

Berger's disease, also known as immunoglobulin A Nephropathy (IgAN), is the most common form of glomerulonephritis, a disorder in which there is non-bacteria-related inflammation of the filtering units (glomeruli) of the kidneys. Whilst IgAN originates in the gut1, it is the kidneys that are damaged. Ultimately, 25-30% of those with IgA Nephropathy develop end-stage renal disease within 20-25 years, requiring dialysis or even kidney transplantation.2 At present, the treatment options for IgA Nephropathy are limited and new forms of treatment approaches are constantly being explored, it is hoped these could at least slow disease progression.

IgA Nephropathy at a glance

Annually reported new cases of IgAN worldwide

~ 2.5/100,000

individuals worldwide develop IgAN every year.3

Annually reported new cases of IgAN in Europe

~ 0.8-2.5/100,000

individuals in Europe develop IgAN every year4

Distribution of cases of IgAN by gender

~ 2 ×

more men than women develop IgAN.5

Age groups in which IgAN tends to be most common

Persons aged 16-35 years

is the age group in which IgAN occurs most frequently.6,7

Learn more about IgAN

Understanding IgAN

Understanding IgAN

Learn more about the most common form of glomerulonephritis worldwide, its epidemiology, its potential progress and the impact associated with IgAN.

Causes of IgA Nephropathy

Causes of IgA Nephropathy

Learn about the pathogenesis of IgA Nephropathy : Learn how IgAN has its origin in the gut, the role played by the peyer’s patches and IgA in the development of the disease and what causative factors there are. 



Obtain an overview of the current gap when it comes to the available treatments of IgA Nephropathy and how the progression of the disease can be predicted.  


  1. Barratt J et al. Why Target the Gut to Treat IgA Nephropathy? Kidney Int Rep 2020; 5(20): 1620–1624.
  2. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100(4S): 1–276.
  3. McGrogan A et al. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26(2): 414–430.
  4. Coppo R. IgA Nephropathy: A European Perspective in the Corticosteroid Treatment. Kidney Dis (Basel) 2018; 4(2): 58-64.
  5. O’Shaughnessy MM et al. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Tranplant 2018; 33(4): 661–669.